<code id='0AF168AC69'></code><style id='0AF168AC69'></style>
    • <acronym id='0AF168AC69'></acronym>
      <center id='0AF168AC69'><center id='0AF168AC69'><tfoot id='0AF168AC69'></tfoot></center><abbr id='0AF168AC69'><dir id='0AF168AC69'><tfoot id='0AF168AC69'></tfoot><noframes id='0AF168AC69'>

    • <optgroup id='0AF168AC69'><strike id='0AF168AC69'><sup id='0AF168AC69'></sup></strike><code id='0AF168AC69'></code></optgroup>
        1. <b id='0AF168AC69'><label id='0AF168AC69'><select id='0AF168AC69'><dt id='0AF168AC69'><span id='0AF168AC69'></span></dt></select></label></b><u id='0AF168AC69'></u>
          <i id='0AF168AC69'><strike id='0AF168AC69'><tt id='0AF168AC69'><pre id='0AF168AC69'></pre></tt></strike></i>

          Home / comprehensive / fashion

          fashion


          fashion

          author:comprehensive    Page View:6
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In